Sage Therapeutics Inc. May Have Violated Securities Law Violations And Investors Are Encouraged To Contribute To A Lawsuit
The Schall Law Firm has announced a class action lawsuit against Sage Therapeutics, Inc. (NASDAQ:SAGE) for alleged violations of securities laws. Investors who purchased Sage securities between April 12, 2021, and July 23, 2024, are encouraged to join the lawsuit before October 28, 2024. The complaint alleges that Sage made false and misleading statements about the effectiveness of its drug Zuranolone for treating major depressive disorder (MDD) and SAGE-718 for mild cognitive impairment (MCI). The lawsuit claims that these misrepresentations led to investor losses when the truth about the drugs' efficacy and FDA approval likelihood was revealed.
Lo Studio Legale Schall ha annunciato una causa collettiva contro Sage Therapeutics, Inc. (NASDAQ:SAGE) per presunti violazioni delle leggi sui titoli. Gli investitori che hanno acquistato titoli Sage tra il 12 aprile 2021 e il 23 luglio 2024 sono incoraggiati a unirsi alla causa prima del 28 ottobre 2024. Il reclamo sostiene che Sage ha rilasciato dichiarazioni false e fuorvianti sull'efficacia del suo farmaco Zuranolone per il trattamento del disturbo depressivo maggiore (MDD) e SAGE-718 per il lieve deterioramento cognitivo (MCI). La causa afferma che queste informazioni errate hanno portato a perdite per gli investitori quando la verità sull'efficacia dei farmaci e la probabilità di approvazione da parte della FDA è stata rivelata.
El bufete de abogados Schall ha anunciado una demanda colectiva contra Sage Therapeutics, Inc. (NASDAQ:SAGE) por supuestas violaciones de las leyes de valores. Se anima a los inversores que compraron valores de Sage entre el 12 de abril de 2021 y el 23 de julio de 2024 a unirse a la demanda antes del 28 de octubre de 2024. La denuncia alega que Sage hizo declaraciones falsas y engañosas sobre la eficacia de su medicamento Zuranolone para el tratamiento del trastorno depresivo mayor (MDD) y SAGE-718 para el deterioro cognitivo leve (MCI). La demanda sostiene que estas tergiversaciones llevaron a pérdidas para los inversores cuando se reveló la verdad sobre la eficacia de los medicamentos y la probabilidad de aprobación por parte de la FDA.
Schall 법률 사무소는 Sage Therapeutics, Inc. (NASDAQ:SAGE)를 상대로 한 집단 소송을 발표했습니다. 2021년 4월 12일부터 2024년 7월 23일 사이에 Sage 증권을 구매한 투자자들은 2024년 10월 28일 이전에 소송에 참여할 것을 권장합니다. 고소장은 Sage가 주요 우울 장애(MDD) 치료를 위한 약물 Zuranolone과 경미한 인지 장애(MCI)를 위한 SAGE-718의 효능에 대해 허위 및 오해의 소지가 있는 진술을 했다고 주장하고 있습니다. 이 소송은 이러한 허위 진술이 약물의 효능과 FDA 승인 가능성에 대한 진실이 드러났을 때 투자자 손실로 이어졌다고 주장합니다.
Le cabinet d'avocats Schall a annoncé une action collective contre Sage Therapeutics, Inc. (NASDAQ:SAGE) pour des violations présumées des lois sur les valeurs mobilières. Les investisseurs ayant acheté des titres Sage entre le 12 avril 2021 et le 23 juillet 2024 sont encouragés à rejoindre l'action en justice avant le 28 octobre 2024. La plainte allègue que Sage a formulé des déchirements faux et trompeurs concernant l'efficacité de son médicament Zuranolone pour traiter le trouble dépressif majeur (MDD) et SAGE-718 pour le léger déclin cognitif (MCI). La plainte affirme que ces déclarations inexactes ont entraîné des pertes pour les investisseurs lorsque la vérité sur l'efficacité des médicaments et la probabilité d'approbation par la FDA a été révélée.
Die Schall Rechtsanwaltskanzlei hat eine Sammelklage gegen Sage Therapeutics, Inc. (NASDAQ:SAGE) wegen angeblicher Verstöße gegen das Wertpapierrecht angekündigt. Investoren, die zwischen dem 12. April 2021 und dem 23. Juli 2024 Sage-Wertpapiere erworben haben, werden ermutigt, sich der Klage vor dem 28. Oktober 2024 anzuschließen. Die Klage behauptet, dass Sage falsche und irreführende Aussagen über die Wirksamkeit seines Medikaments Zuranolone zur Behandlung von Major Depressive Disorder (MDD) und SAGE-718 bei leichter kognitiver Beeinträchtigung (MCI) gemacht hat. Die Klage führt an, dass diese falschen Angaben zu Verlusten bei den Investoren führten, als die Wahrheit über die Wirksamkeit der Medikamente und die Wahrscheinlichkeit einer Genehmigung durch die FDA bekannt wurde.
- None.
- Class action lawsuit filed against Sage Therapeutics for alleged securities law violations
- Allegations of false and misleading statements about drug effectiveness
- Potential investor losses due to misrepresentation of Zuranolone and SAGE-718 efficacy
- Risk of legal and financial consequences for the company
Insights
This class action lawsuit against Sage Therapeutics raises significant concerns for investors. The allegations of false and misleading statements regarding the efficacy of Zuranolone for MDD and SAGE-718 for MCI are particularly troubling. If proven true, these claims could have substantial legal and financial implications for the company.
The lawsuit's focus on the period between April 12, 2021 and July 23, 2024, suggests a prolonged period of potential misinformation. This extended timeframe may increase the potential damages for affected shareholders. The involvement of the Schall Law Firm, known for specializing in securities class actions, adds credibility to the case.
Investors should closely monitor this situation, as the outcome could impact Sage's stock price and future operations. However, it's important to remember that at this stage, these are allegations and the class has not yet been certified. The legal process will determine the validity of these claims.
The legal action against Sage Therapeutics poses significant financial risks for the company. If the allegations are proven, Sage could face substantial monetary penalties and reputational damage. This could lead to a decline in investor confidence and potentially impact the company's ability to raise capital in the future.
The focus on Zuranolone and SAGE-718, key products in Sage's pipeline, is particularly concerning. Any doubts about the efficacy of these drugs could negatively affect the company's revenue projections and market valuation. Investors should carefully assess the potential impact on Sage's financial health and growth prospects.
It's important to note that legal proceedings can be lengthy and costly, potentially diverting resources from R&D and other core business activities. This situation warrants close scrutiny of Sage's upcoming financial reports and any updates on the legal proceedings.
The allegations regarding the efficacy of Zuranolone for MDD and SAGE-718 for MCI are concerning from a medical research perspective. If these claims are substantiated, it could significantly impact Sage's drug development pipeline and credibility in the pharmaceutical industry.
The suggestion that the FDA was unlikely to approve the NDA for Zuranolone is particularly alarming. This implies potential issues with the clinical trial data or the drug's safety profile. It's important for investors to closely monitor any upcoming FDA decisions or communications regarding these drugs.
This situation highlights the inherent risks in pharmaceutical research and development. It underscores the importance of transparent and accurate reporting of clinical trial results. The outcome of this case could have broader implications for how pharmaceutical companies communicate their research findings to investors and the public.
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Sage's Zuranolone proved to be less effective in the treatment of major depressive disorder ("MDD") than the Company had touted to investors. The FDA was unlikely to approve an NDA for Zuranolone. The Company's SAGE-718 was less effective in treating mild cognitive impairment ("MCI") than the company led shareholders to believe. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Sage, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
SOURCE: The Schall Law Firm
View the original press release on accesswire.com
FAQ
What are the allegations against Sage Therapeutics (SAGE) in the class action lawsuit?
What is the class period for the Sage Therapeutics (SAGE) lawsuit?
When is the deadline for investors to join the Sage Therapeutics (SAGE) class action lawsuit?
What specific claims does the lawsuit make about Sage Therapeutics' (SAGE) drug Zuranolone?
